Study of Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid Cancer

Inclusion Criteria:

1. Signed informed consent must be obtained prior to performing any specific pre-screening and screening procedure
2. Male or female >= 18 years of age at the time of informed consent
3. Histologically or cytologically confirmed diagnosis of advanced/metastatic differentiated thyroid cancer
4. Radio active iodine refractory disease
5. BRAFV600E mutation positive tumor sample as per Novartis designated central laboratory result
6. Has progressed on at least 1 but not more than 2 prior VEGFR targeted therapy
7. Eastern Cooperative Oncology Group performance status >= 2
8. At least one measurable lesion as defined by RECIST 1.1

Exclusion Criteria:

1. Anaplastic or medullary carcinoma of the Tyroid
2. Previous treatment with BRAF inhibitor and/or MEK inhibitor
3. Concomitant RET Fusion Positive Thyroid cancer
4. Receipt of any type of small molecule kinase inhibitor within 2 weeks before randomization
5. Receipt of any type of cancer antibody or systemic chemotherapy within 4 weeks before randomization
6. Receipt of radiation therapy for bone metastasis within 2 weeks or any other radiation therapy within 4 weeks before randomization
7. A history or current evidence/risk of retinal vein occlusion or central serous retinopathy